If this email is not displayed correctly please click here

Healthcare & Life Sciences

08 April 2020
Jonas Löfgren Biosimilars still not subject to mandatory substitution

Sweden - Westerberg & Partners Advokatbyrå Ab

Both the Medical Products Agency and the Dental and Benefits Agency (the authority which decides on reimbursement) have long held the position that biosimilars are not interchangeable or substitutable with their reference products, which has been reiterated in different policy papers since 2007. This position has now been supported by an administrative court of appeal in a case relating to glatiramer acetate products used for the treatment of multiple sclerosis.

Authors: Jonas Löfgren, Siri Alvsing
Read more

Recent updates

Andreas Wildi CAR-T therapies and changes to Healthcare Benefits Ordinance

Switzerland - Walder Wyss

Author: Andreas Wildi
Chen Li OCT benefits cap and private label product restrictions abolished

Canada - Smart & Biggar

Authors: Chen Li, Alice Tseng
Adam Bell COVID-19 Weekly Report (23-30 March 2020)

International - International Law Office

Author: Adam Bell
Riccardo Fruscalzo AIFA guidance on management of clinical trials during COVID-19 emergency

Italy - Hogan Lovells

Authors: Riccardo Fruscalzo, Carlotta Busani
Catherine Drew COVID-19 crisis: clinical trials and cross-border collaboration

United Kingdom - Pinsent Masons

Author: Catherine Drew
Anne-Sophie Raxhon DPA approves draft act prohibiting life and health insurers from processing health tracker data

Belgium - ALTIUS

Authors: Anne-Sophie Raxhon, Jan Clinck
Rainer Herzig Leucopenia medicine and reimbursement code

Austria - Preslmayr Attorneys at Law

Author: Rainer Herzig